News

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Results demonstrated that those with earlier asthma onset had slower development of episodic memory.

A new study highlights how depression may drive dysmenorrhea through shared genetic pathways, emphasizing the need for mental health screening and holistic care for women.

In our latest roundtable series, we cover different therapies around COVID-19 treatment and prevention.

Both monthly migraine days and headache days were reduced vs placebo in patients aged 6 to 17 years.

101-PGC-005 is Type IA prodrug of dexamethasone that targets CD206+ macrophages.

If approved, SL1009 has the potential to be the first approved medication for PDCD, and would be available as an oral solution.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Practicing gratitude boosts wellbeing, improves sleep, and reduces stress. Parents can foster it daily by modeling gratitude, helping others, and reflecting on positives.

The most common reactions reported were the following: irritability or fussiness (30.1%), local reactions (21.1%) and fever (13.8%).

Results demonstrated that slowed aperiodic activity was present in brain areas linked to concussion symptoms such as impaired concentration and memory.

Paul Kruszka, MD, MPH, FACMG, explains for general providers the difference between screening and diagnosis regarding whole genome sequencing and how it could play a role in the primary care setting.

In this video interview, Herbert Bravo, MD, explains how implementing autoimmune diabetes screenings in the primary care setting can benefit the child several ways.

A recent study suggests the ketogenic diet could positively impact menstrual cycles by boosting ketones, potentially unlocking new therapeutic insights for women’s reproductive health.

Contemporary Pediatrics' editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses the recent uptick in pediatric vaccine exemptions in this video interview.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from last week, all in one place.

Reportedly, the child experienced mild symptoms and has received flu antivirals.

A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.

Currently, there are no treatments for the serious, rare pediatric disease.

From 2017-2018, antiviral treatment of hospitalized children with influenza ranged from 70%-86%. In the 2023-2024 season, it was less than 60%.

Paul Kruszka, MD, MPH, FACMG, chief medical officer of GeneDx, joined us to provide background of whole genome sequencing and its benefits.

Once-daily icotrokinra versus placebo demonstrated clinically significant skin clearance in those with moderate-to-severe plaque psoriasis.

A further understanding of the role SARS-CoV-2 plays in T2D incidence can add an important component to benefit and risk considerations to prevent COVID-19.

Stephanie Anne Deutsch, MD, MS, MSCR, FAAP, joined us to discuss a new study that highlighted SUID among infants who were prenatally substance exposed.

H. Westley Phillips, MD, explains why awareness and availability of epilepsy surgery is important for pediatric providers among drug-resistant epilepsy patients.

Results demonstrated that daily oral infigratinib treatment led to increases in annualized height velocity and improvement in body proportionality.

David Turkewitz, MD, explains how getting involved in the community to advocate for SUID awareness can make a difference in outcomes for the infant population.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from last week, all in one place.

With this expanded FDA clearance, the wearable becomes the first FDA-cleared, non-drug therapy to treat acute migraines in children.

The application indication is for adults and pediatric patients aged 12 years and older with CSU whose disease is not adequately controlled with H1 antihistamines.